OrganiGram Holdings (TSXV: OGI), the Materials sector company, has received a rating update from a Wall Street analyst today. The company received a Buy rating from Canaccord Genuity’s analyst Matt Bottomley, with a C$6 price target.

Bottomley has an average return of 44.5% when recommending OrganiGram Holdings.

According to TipRanks.com, Bottomley is ranked #137 out of 4801 analysts.

Read also: Gold Prices: What Are the Market Factors That Are Driving Current Fluctuations?

OrganiGram Holdings has an analyst consensus of Moderate Buy, with a price target consensus of C$6.50.

OrganiGram Holdings’ market cap is currently C$597.8M and has a P/E ratio of 0. The company has a Price to Book ratio of 3.72.

OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. Through Organigram Inc., its main focus is on the production of condition specific medical marijuana for patients in Canada. The company was founded on August 22, 2014 and is headquartered in Moncton, Canada.

The company’s shares closed on Friday at C$4.80.